Reports Q3 revenue $43.3M, consensus $39.35M. Announced positive top-line results for MOTION Pivotal Phase 3 Study of Vimseltinib for TGCT and updated results from Phase 1/2 Study; NDA submission expected in second quarter of 2024 . As of September 30 , cash, cash equivalents, and marketable securities were $376.9 million, compared to $389.4M as of June 30, 2023. Based on its current operating plans, Deciphera expects its current cash, cash equivalents, and marketable securities together with anticipated product, royalty, and supply revenues, but excluding any potential future milestones received under its collaboration or license agreements, will enable the Company to fund its operating and capital expenditures into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
